Catalyst Pharmaceuticals (CPRX) Research & Development (2010 - 2026)

Catalyst Pharmaceuticals has reported Research & Development for 17 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 31.54% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 17.71% YoY), and the FY2025 full-year result was $12.7 million, changed 0.48% from the prior year.
• Research & Development for Q1 2026 stood at $2.7 million, up from $1.8 million in the prior quarter.
• The five-year high for Research & Development was $83.7 million in Q3 2023, with the low at $1.8 million in Q4 2025.
• Historically, Research & Development has averaged $8.3 million across 5 years, with a median of $3.6 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development surged 906.76% — and 2024, when it tumbled 96.07%.
• Catalyst Pharmaceuticals' Research & Development stood at $4.1 million in 2022, then plunged by 51.82% to $2.0 million in 2023, then surged by 92.6% to $3.8 million in 2024, then tumbled by 52.42% to $1.8 million in 2025, then surged by 47.26% to $2.7 million in 2026.
• The last three Research & Development figures came in at $2.7 million (Q1 2026), $1.8 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.